Sera Prognostics (NASDAQ:SERA) CEO Zhenya Lindgardt Sells 28,215 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 28,215 shares of Sera Prognostics stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $3.04, for a total transaction of $85,773.60. Following the sale, the chief executive officer directly owned 768,081 shares in the company, valued at approximately $2,334,966.24. The trade was a 3.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Zhenya Lindgardt also recently made the following trade(s):

• On Thursday, September 11th, Zhenya Lindgardt sold 3,246 shares of Sera Prognostics stock. The stock was sold at an average price of $3.13, for a total value of $10,159.98.

Sera Prognostics Trading Up 10.7%

SERA stock traded up $0.33 during midday trading on Wednesday, hitting $3.40. 121,326 shares of the company’s stock were exchanged, compared to its average volume of 29,844. Sera Prognostics, Inc. has a 1-year low of $1.37 and a 1-year high of $9.13. The stock has a market capitalization of $131.24 million, a PE ratio of -4.42 and a beta of 0.97. The business has a 50-day simple moving average of $3.18 and a two-hundred day simple moving average of $2.79.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.03. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.10 million. Sera Prognostics had a negative return on equity of 41.69% and a negative net margin of 34,343.16%. As a group, research analysts expect that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Institutional Trading of Sera Prognostics

A number of large investors have recently modified their holdings of the stock. AWM Investment Company Inc. raised its position in shares of Sera Prognostics by 48.1% during the 1st quarter. AWM Investment Company Inc. now owns 866,837 shares of the company’s stock worth $3,190,000 after acquiring an additional 281,703 shares in the last quarter. Ghisallo Capital Management LLC purchased a new position in Sera Prognostics in the first quarter valued at approximately $368,000. Aberdeen Group plc purchased a new position in Sera Prognostics in the first quarter valued at approximately $4,563,000. Sanders Morris Harris LLC raised its holdings in Sera Prognostics by 179.8% during the second quarter. Sanders Morris Harris LLC now owns 263,600 shares of the company’s stock worth $730,000 after purchasing an additional 169,400 shares in the last quarter. Finally, Wagner Wealth Management LLC purchased a new stake in shares of Sera Prognostics during the 2nd quarter worth approximately $34,000. Hedge funds and other institutional investors own 54.64% of the company’s stock.

Analyst Upgrades and Downgrades

SERA has been the subject of several research analyst reports. Wall Street Zen raised shares of Sera Prognostics from a “sell” rating to a “hold” rating in a research note on Saturday, October 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sera Prognostics in a research report on Monday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.